Cereton, 400 mg capsules 56 pcs

Pharmacotherapeutic group: nootropic

ATX code: N07AX02

Pharmacological properties
.Pharmacodynamics

Notropic. A central cholinostimulant containing 40.5% metabolically protected choline. Metabolic
protection promotes the release of choline in the brain. Provides synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates reticular formation. It increases linear
velocity of blood flow on the side of traumatic brain injury, promotes normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain, regression of focal neurological symptoms and restoration of consciousness; it has a positive effect on the cognitive and behavioral reactions of patients with cerebral vascular disease (discirculatory encephalopathy and
residual effects of circulatory disorders of the brain). It has preventive and corrective effect on pathogenetic factors of involutional psychoorganic syndrome, changes phospholipid composition of neuronal membranes: participates in the synthesis of phosphatidylcholine (membrane phospholipid), improves neuronal membrane plasticity.
Stimulates dose-dependent release of acetylcholine in physiological conditions, improves synaptic transmission and receptor function. It has no effect on the reproductive cycle and has no teratogenic, mutagenic action.

Pharmacokinetics

In parenteral administration (10 mg/kg), Cereton® predominantly accumulates in the brain, lungs and liver. Absorption is 88%, easily penetrates through the blood-brain barrier (when administered orally, its concentration in the brain is 45% of that in plasma). The lungs excrete 85% of the drug as carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Synopsis

Contraindications

Side effects

Overdose

Similarities